Omnicell, Inc. $OMCL Shares Purchased by Legal & General Group Plc

Legal & General Group Plc increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 12.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 178,383 shares of the company’s stock after buying an additional 19,984 shares during the quarter. Legal & General Group Plc’s holdings in Omnicell were worth $8,081,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Assenagon Asset Management S.A. boosted its stake in Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after buying an additional 117,556 shares in the last quarter. Dana Investment Advisors Inc. bought a new position in Omnicell during the fourth quarter valued at about $3,445,000. Peregrine Capital Management LLC bought a new position in Omnicell during the fourth quarter valued at about $4,804,000. Dynamic Technology Lab Private Ltd boosted its stake in Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock valued at $971,000 after buying an additional 24,738 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock valued at $6,343,000 after buying an additional 58,193 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 15,520 shares of company stock valued at $607,610. 2.92% of the stock is owned by insiders.

Omnicell Trading Down 1.4%

OMCL stock opened at $43.00 on Friday. The company has a market cap of $1.96 billion, a P/E ratio of 97.73, a PEG ratio of 1.13 and a beta of 0.97. Omnicell, Inc. has a twelve month low of $26.84 and a twelve month high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The business has a fifty day moving average of $39.86 and a 200-day moving average of $41.32.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm’s quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities research analysts expect that Omnicell, Inc. will post 1.31 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wells Fargo & Company boosted their target price on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. UBS Group set a $60.00 target price on shares of Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Craig Hallum reissued a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. Finally, Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Buy” and an average price target of $59.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.